Laura Chico
Stock Analyst at Wedbush
(3.35)
# 1,191
Out of 4,479 analysts
164
Total ratings
46.23%
Success rate
2.38%
Average return
Main Sectors:
31 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIGL Vigil Neuroscience | Maintains: Outperform | $22 → $23 | $4.01 | +474.28% | 6 | Jun 28, 2024 | |
| EWTX Edgewise Therapeutics | Reiterates: Outperform | $31 | $18.38 | +68.66% | 7 | Jun 26, 2024 | |
| AVTE Aerovate Therapeutics | Reiterates: Outperform | $41 | $1.62 | +2,430.86% | 3 | Jun 6, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Neutral | $47 → $48 | $40.96 | +17.19% | 9 | May 31, 2024 | |
| NBIX Neurocrine Biosciences | Reiterates: Outperform | $152 | $137.49 | +10.55% | 7 | May 29, 2024 | |
| ARDX Ardelyx | Reiterates: Outperform | $15 | $5.28 | +184.09% | 11 | May 24, 2024 | |
| PEPG PepGen | Reiterates: Outperform | $20 | $16.32 | +22.55% | 7 | May 15, 2024 | |
| VYGR Voyager Therapeutics | Maintains: Neutral | $10 → $8 | $7.59 | +5.40% | 2 | May 14, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $33 → $38 | $26.27 | +44.65% | 4 | May 10, 2024 | |
| ATXS Astria Therapeutics | Reiterates: Outperform | $22 | $8.97 | +145.26% | 7 | May 10, 2024 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $51 → $50 | $36.56 | +36.76% | 7 | May 10, 2024 | |
| PHVS Pharvaris | Maintains: Outperform | $35 → $31 | $16.85 | +83.98% | 5 | May 9, 2024 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $31 → $30 | $21.74 | +37.99% | 6 | May 8, 2024 | |
| GOSS Gossamer Bio | Reiterates: Outperform | $4 | $0.96 | +316.75% | 2 | May 8, 2024 | |
| LBPH Longboard Pharmaceuticals | Maintains: Outperform | $32 → $34 | $30.74 | +10.61% | 5 | May 3, 2024 | |
| BIIB Biogen | Maintains: Neutral | $213 → $215 | $228.82 | -6.04% | 12 | Apr 25, 2024 | |
| TVTX Travere Therapeutics | Reiterates: Outperform | $13 | $8.09 | +60.69% | 7 | Apr 17, 2024 | |
| SAGE Sage Therapeutics | Reiterates: Neutral | $24 | $10.82 | +121.81% | 5 | Apr 17, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $67 → $57 | $34.98 | +62.95% | 11 | Apr 17, 2024 | |
| RLYB Rallybio | Maintains: Outperform | $13 → $11 | $1.20 | +816.67% | 4 | Apr 11, 2024 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $8 | $0.77 | +934.39% | 1 | Apr 5, 2024 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $13 → $17 | $12.83 | +32.50% | 5 | Mar 26, 2024 | |
| VERA Vera Therapeutics | Maintains: Neutral | $21 → $34 | $34.93 | -2.66% | 6 | Mar 21, 2024 | |
| DSGN Design Therapeutics | Reiterates: Neutral | $5 | $3.20 | +56.25% | 5 | Mar 20, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $39 → $40 | $12.16 | +228.95% | 6 | Feb 28, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Neutral | $16 → $29 | $39.27 | -26.15% | 5 | Jan 12, 2024 | |
| BMRN BioMarin Pharmaceutical | Initiates: Market Perform | n/a | $82.22 | - | 4 | Sep 28, 2023 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $9 → $5 | $2.16 | +131.48% | 2 | Aug 12, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Downgrades: Neutral | $149 | $34.17 | +334.59% | 1 | Aug 8, 2022 | |
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Outperform | n/a | $48.01 | - | 1 | Jan 19, 2018 | |
| CDTX Cidara Therapeutics | Initiates: Strong Buy | $280 | $11.93 | +2,247.02% | 1 | Apr 21, 2017 |
Vigil Neuroscience
Jun 28, 2024
Maintains: Outperform
Price Target: $22 → $23
Current: $4.01
Upside: +474.28%
Edgewise Therapeutics
Jun 26, 2024
Reiterates: Outperform
Price Target: $31
Current: $18.38
Upside: +68.66%
Aerovate Therapeutics
Jun 6, 2024
Reiterates: Outperform
Price Target: $41
Current: $1.62
Upside: +2,430.86%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Neutral
Price Target: $47 → $48
Current: $40.96
Upside: +17.19%
Neurocrine Biosciences
May 29, 2024
Reiterates: Outperform
Price Target: $152
Current: $137.49
Upside: +10.55%
Ardelyx
May 24, 2024
Reiterates: Outperform
Price Target: $15
Current: $5.28
Upside: +184.09%
PepGen
May 15, 2024
Reiterates: Outperform
Price Target: $20
Current: $16.32
Upside: +22.55%
Voyager Therapeutics
May 14, 2024
Maintains: Neutral
Price Target: $10 → $8
Current: $7.59
Upside: +5.40%
Dianthus Therapeutics
May 10, 2024
Maintains: Outperform
Price Target: $33 → $38
Current: $26.27
Upside: +44.65%
Astria Therapeutics
May 10, 2024
Reiterates: Outperform
Price Target: $22
Current: $8.97
Upside: +145.26%
Xenon Pharmaceuticals
May 10, 2024
Maintains: Outperform
Price Target: $51 → $50
Current: $36.56
Upside: +36.76%
Pharvaris
May 9, 2024
Maintains: Outperform
Price Target: $35 → $31
Current: $16.85
Upside: +83.98%
Denali Therapeutics
May 8, 2024
Maintains: Outperform
Price Target: $31 → $30
Current: $21.74
Upside: +37.99%
Gossamer Bio
May 8, 2024
Reiterates: Outperform
Price Target: $4
Current: $0.96
Upside: +316.75%
Longboard Pharmaceuticals
May 3, 2024
Maintains: Outperform
Price Target: $32 → $34
Current: $30.74
Upside: +10.61%
Biogen
Apr 25, 2024
Maintains: Neutral
Price Target: $213 → $215
Current: $228.82
Upside: -6.04%
Travere Therapeutics
Apr 17, 2024
Reiterates: Outperform
Price Target: $13
Current: $8.09
Upside: +60.69%
Sage Therapeutics
Apr 17, 2024
Reiterates: Neutral
Price Target: $24
Current: $10.82
Upside: +121.81%
Apellis Pharmaceuticals
Apr 17, 2024
Maintains: Neutral
Price Target: $67 → $57
Current: $34.98
Upside: +62.95%
Rallybio
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $1.20
Upside: +816.67%
Ovid Therapeutics
Apr 5, 2024
Initiates: Outperform
Price Target: $8
Current: $0.77
Upside: +934.39%
Stoke Therapeutics
Mar 26, 2024
Maintains: Outperform
Price Target: $13 → $17
Current: $12.83
Upside: +32.50%
Vera Therapeutics
Mar 21, 2024
Maintains: Neutral
Price Target: $21 → $34
Current: $34.93
Upside: -2.66%
Design Therapeutics
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $3.20
Upside: +56.25%
Viridian Therapeutics
Feb 28, 2024
Maintains: Outperform
Price Target: $39 → $40
Current: $12.16
Upside: +228.95%
Praxis Precision Medicines
Jan 12, 2024
Maintains: Neutral
Price Target: $16 → $29
Current: $39.27
Upside: -26.15%
BioMarin Pharmaceutical
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $82.22
Upside: -
Taysha Gene Therapies
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $2.16
Upside: +131.48%
Biohaven Pharmaceutical Holding Company
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $34.17
Upside: +334.59%
Corbus Pharmaceuticals Holdings
Jan 19, 2018
Initiates: Outperform
Price Target: n/a
Current: $48.01
Upside: -
Cidara Therapeutics
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $11.93
Upside: +2,247.02%